T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$2.16B |
| 2 |
GE Aerospace
GE
|
+$1.93B |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$1.62B |
| 4 |
Eli Lilly
LLY
|
+$1.59B |
| 5 |
SPLK
Splunk Inc
SPLK
|
+$1.38B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$2.72B |
| 2 |
Booking.com
BKNG
|
+$2.61B |
| 3 |
RHT
Red Hat Inc
RHT
|
+$1.62B |
| 4 |
JPMorgan Chase
JPM
|
+$1.43B |
| 5 |
State Street
STT
|
+$1.29B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.85% |
| 2 | Technology | 18.49% |
| 3 | Financials | 14.29% |
| 4 | Consumer Discretionary | 14.06% |
| 5 | Communication Services | 9.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1301
Sprott Physical Gold and Silver Trust
CEF
$8.26B
| $9.88M | ﹤0.01% |
787,500
-559,100
| -42% | -$6.63M |
|
1302
Denali Therapeutics
DNLI
$3.9B
| $9.86M | ﹤0.01% |
477,242
+1,175
| +0.2% | +$21.3K |
|
1303
Capri Holdings
CPRI
$1.75B
| $9.85M | ﹤0.01% |
259,855
+920
| +0.4% | +$46.3K |
|
1304
H&R Block
HRB
$6.78B
| $9.84M | ﹤0.01% |
387,772
| – | – |
|
1305
Aaon
AAON
$7.17B
| $9.83M | ﹤0.01% |
420,459
+4,083
| +1% | +$98.1K |
|
|
WLL
1306
DELISTED
Whiting Petroleum Corporation
WLL
| $9.75M | ﹤0.01% |
5,728
+631
| +12% | +$1.62M |
|
|
PBCT
1307
DELISTED
People's United Financial Inc
PBCT
| $9.74M | ﹤0.01% |
674,898
+104,067
| +18% | +$1.65M |
|
|
KW
1308
DELISTED
Kennedy-Wilson Holdings
KW
| $9.68M | ﹤0.01% |
532,950
+8,179
| +2% | +$157K |
|
|
JWN
1309
DELISTED
Nordstrom
JWN
| $9.66M | ﹤0.01% |
207,250
+10,300
| +5% | +$581K |
|
|
FPRX
1310
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $9.61M | ﹤0.01% |
1,033,318
-7,936
| -0.8% | -$94.4K |
|
1311
Markel Group
MKL
$22.8B
| $9.57M | ﹤0.01% |
9,222
+1,381
| +18% | +$1.51M |
|
1312
Endava
DAVA
$163M
| $9.55M | ﹤0.01% |
393,992
+3,600
| +0.9% | +$88.3K |
|
1313
AngioDynamics
ANGO
$646M
| $9.54M | ﹤0.01% |
473,815
+1,601
| +0.3% | +$33.1K |
|
1314
Central Garden & Pet Co Class A
CENTA
$2.38B
| $9.53M | ﹤0.01% |
381,134
+6,189
| +2% | +$148K |
|
1315
Affiliated Managers Group
AMG
$9.78B
| $9.52M | ﹤0.01% |
97,723
+495
| +0.5% | +$55.9K |
|
|
APLS
1316
DELISTED
Apellis Pharmaceuticals
APLS
| $9.48M | ﹤0.01% |
718,883
-191,676
| -21% | -$2.94M |
|
|
APTX
1317
DELISTED
Aptinyx Inc. Common Stock
APTX
| $9.39M | ﹤0.01% |
567,990
+4,894
| +0.9% | +$116K |
|
1318
BHP
BHP
$220B
| $9.22M | ﹤0.01% |
214,109
+10,270
| +5% | +$430K |
|
1319
NCS Multistage Holdings
NCSM
$134M
| $9.21M | ﹤0.01% |
90,458
-3,172
| -3% | -$609K |
|
|
MDSO
1320
DELISTED
Medidata Solutions, Inc.
MDSO
| $9.16M | ﹤0.01% |
135,899
-3,862
| -3% | -$273K |
|
1321
Donaldson
DCI
$11.1B
| $9.03M | ﹤0.01% |
208,060
-10,971
| -5% | -$567K |
|
1322
Federal Signal
FSS
$7.64B
| $9M | ﹤0.01% |
452,043
+425,752
| +1,619% | +$9.7M |
|
1323
RPC Inc
RES
$1.42B
| $8.87M | ﹤0.01% |
898,805
-7,075
| -0.8% | -$96.2K |
|
1324
TripAdvisor
TRIP
$1.28B
| $8.83M | ﹤0.01% |
163,695
+90
| +0.1% | +$4.98K |
|
1325
Tandem Diabetes Care
TNDM
$1.59B
| $8.63M | ﹤0.01% |
227,390
-19,502
| -8% | -$689K |
|
Similar funds
T. Rowe Price Associates's Q4 2018 Portfolio in Review
As of Q4 2018, T. Rowe Price Associates held 2,656 positions worth $591B, down 14% from $685B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
T. Rowe Price Associates's Q4 2018 filing shows 75 new, 1,551 increased, 819 reduced and 97 closed positions. Its largest new stake was StoneCo: 28,883,228 shares worth $519M. The largest sale was Tesla, an estimated $2.72B.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 18% a quarter earlier, followed by Technology and Financials.
- T. Rowe Price Associates's largest Q4 2018 buy was StoneCo: 28,883,228 shares worth $519M.
- T. Rowe Price Associates added most to Meta Platforms (Facebook) in Q4 2018, an estimated $2.16B increase.
- T. Rowe Price Associates's biggest Q4 2018 reduction was Tesla, cutting an estimated $2.72B.
- T. Rowe Price Associates fully exited Aetna Inc in Q4 2018, selling an estimated $600M.
- T. Rowe Price Associates's ten largest holdings make up 20% of its $591B portfolio in Q4 2018.
- T. Rowe Price Associates opened 75 new positions and closed 97 in Q4 2018.
- T. Rowe Price Associates's portfolio value fell 14% quarter-over-quarter to $591B.
Based on T. Rowe Price Associates's 13F filing for Q4 2018, filed 14 Feb 2019.